| | | | | | | | Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 29 |
|
|
|
| |
| | |
|
|
| | | | | The drug was a driving force behind AstraZeneca's recent $1.05 billion acquisition of Amolyt. |
|
|
| In a deal that could reach $1.75 billion, Novartis picks up a pipeline of novel radioligand therapies to treat cancers with high unmet need. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Upholding rigorous quality standards is not only a regulatory imperative but also vital for ensuring the efficacy and safety of pharmaceutical products. And as many pharma manufacturers have discovered, enhanced quality processes can also unlock significant performance improvements.But quality improvements... |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
